MK-0457: A light at the end of the tunnel?

Blood

Volumn 109, Issue 2, 2007, Pages 396-397

  Martinelli, Giovanni ^a   Soverini, Simona ^a   Iacobucci, Ilaria ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; IMATINIB; ISOLEUCINE; NILOTINIB; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; THREONINE;

ACUTE LYMPHOCYTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG SPECIFICITY; DRUG STRUCTURE; GENE MUTATION; HEALTH PRACTITIONER; HUMAN; HYDROGEN BOND; NOTE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 33846225953     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-049320     Document Type: Note

References (5)

1. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
2. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
3. Pricl S, Fermeglia M, Ferrone M, et al. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol Cancer Ther. 2005;4:1167-1174.
4. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA. 2005;102:11011-11016.
5. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006;66:1007-1014.